Thermo Fisher CEO Casper Marc N sells, buys shares in company stock.

Thermo Fisher Scientific Inc. (TMO) has recently announced that Marc N. Casper, the company's Director, Chairman, and Chief Executive Officer, has made certain transactions involving the purchase and sale of shares. Specifically, on September 5, 2025, Mr. Casper acquired 400 shares at a price of $253.99 per share. Additionally, he sold 200 shares at a price of $500 per share, as well as 100 shares at $501 per share and 100 shares at $501.01 per share, all on the same date.

Title: Thermo Fisher Scientific's CEO, Marc N. Casper, Engages in Strategic Share Transactions

Thermo Fisher Scientific Inc. (TMO), a leading provider of life sciences solutions, has recently seen its shares traded by its CEO, Marc N. Casper. On September 5, 2025, Casper executed a series of transactions involving the purchase and sale of shares. This move has sparked interest among investors and financial professionals.

Casper acquired 400 shares at a price of $253.99 per share, while also selling 200 shares at $500 per share, 100 shares at $501 per share, and 100 shares at $501.01 per share, all on the same date Thermo Fisher Plummets 1.05% on $630M Trading Volume Ranked 165th as Acquisition Expands U.S. Pharma Manufacturing Footprint^[1]. These transactions represent a strategic shift in his investment portfolio, potentially signaling his confidence in the company's future prospects.

The stock's performance has been robust, with a market cap of $185.86 billion and a PE ratio of 28.47. The company's recent quarterly earnings report showed revenue of $10.86 billion, surpassing estimates by $1.18 billion, and an EPS of $5.36, which exceeded expectations by $0.14 Thermo Fisher Plummets 1.05% on $630M Trading Volume Ranked 165th as Acquisition Expands U.S. Pharma Manufacturing Footprint^[1]. Despite the strong financial performance, analysts have mixed views on the stock's future. While some have upgraded their ratings, others have maintained their "hold" or "overweight" positions, indicating varying degrees of optimism.

The acquisition of Sanofi's Ridgefield, NJ facility by Thermo Fisher Scientific has further expanded the company's pharma manufacturing footprint. This strategic move adds 200+ staff and boosts sterile fill-finish capacity for biotech clients, aligning with the company's $40B+ revenue strategy Thermo Fisher Plummets 1.05% on $630M Trading Volume Ranked 165th as Acquisition Expands U.S. Pharma Manufacturing Footprint^[1]. However, integration and market risk challenges are expected to be part of the process.

Institutional investors have also shown interest in Thermo Fisher Scientific, with Scientech Research LLC increasing its stake by 87.4% in Q1, bringing its total holdings to 5,122 shares valued at approximately $2.55 million Thermo Fisher Scientific Inc. $TMO Shares Bought by ...^[2]. Other institutional investors, such as Revolve Wealth Partners LLC and Port Capital LLC, have also increased their holdings in the company.

Despite the recent insider transactions, Thermo Fisher Scientific remains a strong player in the life sciences industry, with a diverse range of products and services. The company's focus on innovation and strategic acquisitions positions it well for future growth.

References
Thermo Fisher Plummets 1.05% on $630M Trading Volume Ranked 165th as Acquisition Expands U.S. Pharma Manufacturing Footprint^[1] https://www.ainvest.com/news/thermo-fisher-plummets-1-05-630m-trading-volume-ranked-165th-acquisition-expands-pharma-manufacturing-footprint-2509/
Thermo Fisher Scientific Inc. $TMO Shares Bought by ...^[2] https://www.marketbeat.com/instant-alerts/filing-thermo-fisher-scientific-inc-tmo-shares-bought-by-scientech-research-llc-2025-09-07/